Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar
Tue, 24/04/2018 - 09:49
0 min
Español
NoticiasWeb_English_0.png
Download related document
Select rating
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 1/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 2/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 3/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 4/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 5/5
No votes yet
Related
First quarter 2023 results press release
ROVI REACHED 201.9 MILLION EUROS OF REVENUE IN THE FIRST POST-PANDEMIC QUARTER Operating revenue decreased by 2% to 201.6 million...
3 min
10/05/2023
ROVI commences clinical development of a new three-monthly formulation of...
ROVI COMMENCES CLINICAL DEVELOPMENT OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE (LETROZOLE LEBE) The objective of the new...
6 min
25/04/2023
Created a Chair to study the psychological impact and benefits of technology in...
Madrid, 12 April, 2023 The Universidad Pontificia Comillas, in collaboration with Laboratorios Farmacéuticos ROVI, has created...
3 min
12/04/2023
See More
Email
Facebook
Twitter
LinkedIn
NoticiasWeb_English_0.png